title: Ninety-day mortality after elective total hip replacement: 1549 patients using aspirin as a thromboprophylactic agent.
abstract: Thromboprophylaxis after elective orthopaedic surgery remains controversial. Recent guidelines from the National Institute for Clinical Excellence (NICE) have suggested that low molecular weight heparin should be given to all patients undergoing total hip replacement. The British Orthopaedic Association is currently debating this guideline with NICE, as it is not clear whether published evidence supports this view. We present the early mortality in our unit after total hip replacement using aspirin as chemical thromboprophylaxis. The 30-day and 90-day mortality after primary total hip arthroplasty was zero. We compare this with that reported previously from our unit without using chemical thromboprophylaxis. With the introduction of routine aspirin thromboprophylaxis, deaths from cardiovascular causes have dropped from 0.75% to zero. These results demonstrate that there is a strong argument for the routine administration of aspirin after elective total hip replacement.
authors.affiliation: University of Bristol, Avon Orthopaedic Centre, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK.
authors.forename: M
authors.initials: M
authors.lastname: Parry
authors.forename: V
authors.initials: V
authors.lastname: Wylde
authors.forename: A W
authors.initials: AW
authors.lastname: Blom
mesh_terms: D019644:Arthroplasty, Replacement, Hip / Q000401:mortality*; D001241:Aspirin / Q000627:therapeutic use*; D004739:England; D005500:Follow-Up Studies; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control*; D013923:Thromboembolism / Q000401:mortality* / Q000517:prevention & control
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin